Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

ENGULF Novel PE Thrombectomy Device Minimizes Blood Loss

News Conference News VIVA 2025

ENGULF Novel PE Thrombectomy Device Minimizes Blood Loss

November 07, 2025

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

November 11, 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

November 05, 2024

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

News Conference News VIVA 2023

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

November 01, 2023

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

News Conference News VIVA 2022

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

November 04, 2022

Vascular Care Falls Short Before Amputation for CLI: Medicare Analysis

News Conference News VIVA 2021

Vascular Care Falls Short Before Amputation for CLI: Medicare Analysis

October 06, 2021

As Paclitaxelgate Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice

News Conference News VIVA 2020

As ‘Paclitaxelgate’ Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice

November 27, 2020

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

News Conference News VIVA 2020

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

November 09, 2020

Future Pulmonary Embolism Interventions: Wild West or Working Together?

News Conference News VIVA 2019

Future Pulmonary Embolism Interventions: Wild West or Working Together?

November 14, 2019

Clinicians Get Real on Radiation: ‘Don’t Do Dumb Things’

News Conference News VIVA 2019

Clinicians Get Real on Radiation: ‘Don’t Do Dumb Things’

November 07, 2019

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

News Conference News VIVA 2019

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

November 05, 2019

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

November 15, 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

November 13, 2018

Attacking DVT With Drug-Device Combo Does Not Reduce Postthrombotic Syndrome

News Conference News VIVA 2018

VERNACULAR: A Novel Venous Stent Shows Promise for Treatment of Iliofemoral Occlusive Disease

November 08, 2018

LUTONIX BTK: Hope for Challenging Patients at High Risk for Amputation

News Conference News VIVA 2018

LUTONIX BTK: Hope for Challenging Patients at High Risk for Amputation

November 07, 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

News Conference News VIVA 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

November 06, 2018

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

September 18, 2017

ACT I: Women Reap More Long-term Benefits From Carotid Stenting vs CEA

News Conference News VIVA 2017

ACT I: Women Reap More Long-term Benefits From Carotid Stenting vs CEA

September 15, 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

September 13, 2017

News Conference News VIVA 2016

Longer Term, IN.PACT SFA Trial and Global Registry Continue to Support DCB Therapy as an Option

October 12, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.